{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"IN8bio, Inc."},"Symbol":{"label":"Symbol","value":"INAB"},"Address":{"label":"Address","value":"350 5TH AVENUE,SUITE 5330, NEW YORK, New York, 10118, United States"},"Phone":{"label":"Phone","value":"+1 646 600-6438"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells."},"CompanyUrl":{"label":"Company Url","value":"https://www.in8bio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Kate Rochlin","title":"Chief Operating Officer"},{"name":"Lawrence S. Lamb","title":"Chief Scientific Officer & Executive VP"},{"name":"Stacey Bilinski","title":"Vice President-Clinical Operations"},{"name":"William T. Ho","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}